Journal profile · Medicine-Immunology and Allergy
Journal of Translational Autoimmunity
ISSN 2589-9090 · Elsevier · Netherlands
Journal of Translational Autoimmunity: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 3.8 (journal website); fully open access; APC about USD 3,540; median 59 days to acceptance (98 articles, last 24 months); 80 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Journal of Translational Autoimmunity is published by Elsevier and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Systemic Lupus Erythematosus Research, Diabetes and associated disorders and T-cell and B-cell Immunology, together about 32.1% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
The Journal of Translational Autoimmunity is a peer-reviewed open access journal that primarily aims to disseminate bench-to-bedside research in autoimmunity. It is a spin-off from the Journal of Autoimmunity, which publishes papers related to the diverse aspects of autoimmunity. The Journal of Translational Autoimmunity considers submissions transferred from the Journal of Autoimmunity as well as direct submissions.The immune system is becoming part of a growing number of other disciplines, so research in the development of autoimmune disease is increasingly important across disciplines. Translational research links basic science with clinical application, showing how the excellent work done in basic science research laboratories around the world is relevant in real life.The Journal of Translational Autoimmunity does not accept manuscripts that consist mainly of bioinformatics analyses or computational studies of public data without following the guidelines for reporting bioinformatic studies (e.g. STROBE-MR) together with appropriate experimental validation.The Journal of Translational Autoimmunity welcomes translational research on the many autoimmune diseases, including (but not limited to):LupusPsoriasisSjogren's syndromeAutoimmune hepatitisType 1 diabetesAutoimmune cytopeniasThe ultimate goal of the journal is to provide readers with relevant information to understand the underlying pathogenesis of this group of common disorders. Authors can submit in various formats, including original research, systematic reviews, letters to the editor, brief communications and case studies or case cohorts. All submitted manuscripts undergo rigorous peer review by experts in the field.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Immunology and Allergy
Editor-in-chief Yves RenaudineauPublisher website
Editorial board by country: none in mainland China; most named France 5, United Kingdom 4, Colombia 4, Vietnam 2, Taiwan, China 1 (23 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Systemic Lupus Erythematosus ResearchMedicine16.7%
- Diabetes and associated disordersBiochemistry, Genetics and Molecular Biology8.2%
- T-cell and B-cell ImmunologyImmunology and Microbiology7.3%
- Liver Diseases and ImmunityMedicine6.8%
- Rheumatoid Arthritis Research and TherapiesMedicine5.6%
- Monoclonal and Polyclonal Antibodies ResearchMedicine4.1%
- Immune Cell Function and InteractionImmunology and Microbiology3.7%
- Systemic Sclerosis and Related DiseasesMedicine3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 3.8Publisher website ·
- CiteScore 2026-06
- 6.2LetPub ·
- CiteScore (publisher)
- 6.2Publisher website ·
- SJR 2026-06
- 1.17LetPub ·
- SNIP 2026-06
- 1.17LetPub ·
- h-index
- 38OpenAlex ·
- i10-index
- 151OpenAlex ·
- 2-year mean citedness
- 3.57OpenAlex ·
- Self-citation rate
- 2.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 73LetPub ·
Articles by year OpenAlex count · 389 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 55 | 55 | 14 |
| 2025 | 80 | 80 | 327 |
| 2024 | 34 | 34 | 262 |
| 2023 | 42 | 42 | 442 |
| 2022 | 46 | 46 | 921 |
| 2021 | 58 | 58 | 1,891 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
59 daysMedian, submission to acceptance · P25–P75 40 days – 79 days
- Acceptance to online
- median 1 days (98 articles)
- Submission to online
- median 61 days
- Sample
- 98 articles with submission and acceptance dates (153 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 11 weeksLetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 29 daysPublisher website ·
- Submission to acceptance
- 61 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 10 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,540 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 3,180 / EUR 2,970 / GBP 2,550 / JPY 394,420 | — | — | |
| LetPub | USD 2,400 | Yes | — | |
| Publisher website | USD 3,770 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Highlights
- Optional
- Cover letter
- Required
Article types accepted2
- research article...Length not stated
- review article...Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of one reviewer for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Rea…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Netherlands
- Language
- English
- ISSN
- 2589-9090
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Translational Autoimmunity
What CAS zone is Journal of Translational Autoimmunity in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Translational Autoimmunity is in Zone 2 of Medicine, and in Zone 3 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Translational Autoimmunity?
The journal's website gives an impact factor of 3.8; this is the journal's own figure, as LetPub lists none for it; CiteScore 6.2, h-index 38.
How long does peer review take at Journal of Translational Autoimmunity?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 59 days (interquartile range 40–79 days); authors report an average review time of about 11 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Journal of Translational Autoimmunity?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; Suggested reviewers: Optional; Highlights: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Journal of Translational Autoimmunity based?
Of the 23 board members whose country the journal's board page names, none are in mainland China; the countries named most often are France (5), United Kingdom (4) and Colombia (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Translational Autoimmunity?
According to LetPub and DOAJ records, Journal of Translational Autoimmunity is indexed in ESCI, Scopus and DOAJ.
Is Journal of Translational Autoimmunity open access, and what is the APC?
Journal of Translational Autoimmunity is a fully open-access journal. APC about USD 3,540.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .